The 2026 ASCO Gastrointestinal Cancers Symposium (ASCO GI 2026) is being held January 8–10, 2026, at Moscone West in San Francisco, California, with both in-person and online participation available for the global GI oncology community.
Building on its reputation as a premier forum for gastrointestinal cancer research and clinical progress, ASCO GI 2026 convenes medical oncologists, surgeons, radiation oncologists, gastroenterologists, pathologists, radiologists, researchers, trainees, and patient advocates to spotlight advances spanning translational science, precision therapies, and multidisciplinary care.
Across scientific sessions, educational programming, and featured abstract presentations, the meeting highlights emerging data and practical insights across the spectrum of GI malignancies supporting timely knowledge-sharing and broad accessibility through its hybrid format.
Wafik El-Deiry, Director of Legorreta Cancer Center at Brown University and Chair of the WIN Consortium in Cancer Personalized Medicine, shared some key highlights from the ASCO GI 2026:
“Great to see my Brown University colleagues Dr. Alex Raufi and Dr. Howard Safran at GI26 in San Francisco.”
“Great to see my colleague Dr. Humaid Al Shamsi, CEO and Director of the Burjeel Cancer Institute and President of the Emirates Oncology Society at ASCO GI26 in San Francisco.”
“Terrific sessions this morning at GI26 with results in resectable and advanced gastric cancer from NEOSUMMIT-01, neoadjuvant therapy CRITICS II, ILUSTRO, and HORIZON-GEA-1 results. Targeting Claudin 18.2 (Zolbetuximab) and Her2 (Zanidatamab) highlighted in the advanced setting.”
“Great to see Dr. Josh Meyer at the podium at GI26 discussing strategies for avoiding esophagectomy in locally advanced gastroesophageal cancer. NeoRes II supported delayed surgery. SANO also supported active surveillance. Important quality of life issues discussed.
Always great to reconnect with colleagues at meetings.”
“Great to see Dr. Steve Cohen who is one of the premiere GI Oncologists in the US now at Jefferson Health previously my colleague when I was at Fox Chase Cancer Center.
Enjoyed our conversation about a variety of topics including new cancer drugs, precision oncology, remembering the late Paul Engstrom (another giant of medical oncology and cancer prevention) and academic life.”
“Love the chicken, falafel and tahini at this Mediterranean restaurant across the street from the Moscone Convention Center GI26 the Mountain Dew is a bonus.”
“Insightful and inspiring presentation by Dr. Kim Rathmell at GI26 about the importance of clinical trials, telehealth, virtual clinical trials office in “Dyad Care” to bridge the divide that leads to disparities in cancer care in rural America . She gave an example of a pancreatic cancer trial with rare FGFR mutations and spoke about early-onset GI cancers.”
“Attending the Caris Life Sciences CARIS Precision Oncology Alliance GI Cancers Working Group meeting this evening in San Francisco with Dr. Safran. Learning about progress in research, technologies and platforms and the impressive evolution of the POA over the last decade. Great to see Drs. Ari VanderWalde and George W Sledge and to have opportunity to discuss collaboration between WIN Consortium and Caris Life Sciences.”
“Spending time with colleagues in GI Oncology Drs. Howard Safran, Rimini Breakstone, and Alex Raufi at The Warren Alpert Medical School of Brown University at GI26.”
“Learning about Lirafugratinib: The First Highly Selective FGFR2 Inhibitor at GI26
93% of tumors shrunk
Efficacy and safety of lirafugratinib in FGFRi-naïve cholangiocarcinoma
(CCA) patients harboring FGFR2 fusions/rearrangements (FGFR2f/r).
Antoine Hollebecque, MD
Gustave Roussy Cancer Institute.”
“Learning about the Preliminary phase 1 results of INCB161734, a novel oral Kirsten rat sarcoma (KRAS) G12D inhibitor, as monotherapy or in combination with chemotherapy for advanced/ metastatic pancreatic duct adenocarcinoma (PDAC).
Zev A. Wainberg, MD
David Geffen School of Medicine”
You can also read: 15 Posts Not To Miss From ASCO GI 2026, part 1
